应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
RNA Avidity Biosciences, Inc.
已收盘 11-14 16:00:00 EST
70.80
-0.04
-0.06%
盘后
70.80
+0.00
0.00%
19:48 EST
最高
71.09
最低
70.59
成交量
239.50万
今开
70.80
昨收
70.84
日振幅
0.71%
总市值
106.68亿
流通市值
80.00亿
总股本
1.51亿
成交额
1.70亿
换手率
2.12%
流通股本
1.13亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Korro Bio的RNA编辑药物例临床结果不佳，引发裁员，诺和诺德暂停合作 | 2025Q3
Minhua笔记 · 11-14 18:13
Korro Bio的RNA编辑药物例临床结果不佳，引发裁员，诺和诺德暂停合作 | 2025Q3
周二关注股票：亚马逊、新纪元、联合健康、英伟达
投资观察 · 10-28
周二关注股票：亚马逊、新纪元、联合健康、英伟达
Avidity Biosciences, Inc.：RBC将其目标评级从“跑赢大盘”下调至“行业表现”，并将目标价从61美元上调至72美元
美股速递 · 10-28
Avidity Biosciences, Inc.：RBC将其目标评级从“跑赢大盘”下调至“行业表现”，并将目标价从61美元上调至72美元
Avidity Biosciences Inc ：Leerink Partners 将评级从“跑赢大盘”下调至“市场表现”；目标价格上调至72美元，从65美元提高
美股速递 · 10-27
Avidity Biosciences Inc ：Leerink Partners 将评级从“跑赢大盘”下调至“市场表现”；目标价格上调至72美元，从65美元提高
诺华首席执行官表示公司计划与美国FDA讨论对Avidity纤维肌痛症治疗的加速审批潜力
美股速递 · 10-27
诺华首席执行官表示公司计划与美国FDA讨论对Avidity纤维肌痛症治疗的加速审批潜力
Avidity Biosciences- 在特定情况下合并与诺华终止时，公司需向诺华支付4.5亿美元的终止费
美股速递 · 10-27
Avidity Biosciences- 在特定情况下合并与诺华终止时，公司需向诺华支付4.5亿美元的终止费
Avidity Biosciences Inc：Bernstein下调评级至市场表现，从跑赢大盘调整至$72目标价
美股速递 · 10-27
Avidity Biosciences Inc：Bernstein下调评级至市场表现，从跑赢大盘调整至$72目标价
120亿美元拿下“罕见病专家”Avidity，医药巨头诺华同意历史上最大笔收购
华尔街见闻 · 10-27
120亿美元拿下“罕见病专家”Avidity，医药巨头诺华同意历史上最大笔收购
石药集团(01093)：SYH2061注射液(双链小干扰RNA药物)在中国获临床试验批准
智通财经 · 10-24
石药集团(01093)：SYH2061注射液(双链小干扰RNA药物)在中国获临床试验批准
Avidity Biosciences宣布Del-Zota治疗DMD44获得美国FDA积极的生物制品许可申请预备会议反馈，计划于2026年第一季度提交申请
美股速递 · 10-13
Avidity Biosciences宣布Del-Zota治疗DMD44获得美国FDA积极的生物制品许可申请预备会议反馈，计划于2026年第一季度提交申请
石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在美国获临床试验批准
智通财经 · 10-09
石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在美国获临床试验批准
石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在中国获临床试验批准
智通财经 · 09-30
石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在中国获临床试验批准
Avidity Biosciences, Inc.盘中异动 股价大跌5.02%
市场透视 · 09-26
Avidity Biosciences, Inc.盘中异动 股价大跌5.02%
募资5亿美元加码核心管线！Avidity(RNA.US)获美银唱好 目标价看高至65美元
智通财经 · 09-15
募资5亿美元加码核心管线！Avidity(RNA.US)获美银唱好 目标价看高至65美元
Avidity宣布已完成6亿美元股票发行的定价
环球市场播报 · 09-12
Avidity宣布已完成6亿美元股票发行的定价
生物技术企业Avidity生物科学公司（RNA）宣布已完成6亿美元股票发行的定价以推进其临床项目并扩大商业基础设施。所筹
智通财经 · 09-12
生物技术企业Avidity生物科学公司（RNA）宣布已完成6亿美元股票发行的定价以推进其临床项目并扩大商业基础设施。所筹
Avidity Biosciences的Del-Zota在Explore44®和Explore44-Ole™ 1/2期试验中证实在关键功能终点实现了Dmd44患者疾病进展的逆转
美股速递 · 09-10
Avidity Biosciences的Del-Zota在Explore44®和Explore44-Ole™ 1/2期试验中证实在关键功能终点实现了Dmd44患者疾病进展的逆转
10x基因组学取得使用RNA模板化连接进行空间分析的方法专利
市场资讯 · 09-06
10x基因组学取得使用RNA模板化连接进行空间分析的方法专利
诺和诺德新CEO上任三把火，5.5亿美元押注RNA技术
MedTrend医趋势 · 08-29
诺和诺德新CEO上任三把火，5.5亿美元押注RNA技术
中慧生物CHO细胞新药临床试验获中美当局批准
格隆汇 · 08-17
中慧生物CHO细胞新药临床试验获中美当局批准
加载更多
公司概况
公司名称：
Avidity Biosciences, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Avidity Biosciences, Inc.是根据特拉华州法律于2012年11月13日成立的。该公司是一家生物制药公司。公司开创了一种新型的基于寡核苷酸的疗法，称为抗体寡核苷酸缀合物（AOC），旨在克服寡核苷酸疗法的当前局限性，以治疗多种严重的疾病。该公司利用其专有的AOC平台来设计，策划和开发结合单克隆抗体（mAbs）的组织选择性和寡核苷酸疗法的精确性的疗法，以访问以前无法吸收的组织和细胞类型，并更有效地针对疾病的潜在遗传驱动因素。
发行价格：
--
{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Avidity Biosciences, Inc.","latestPrice":70.8,"timestamp":1763154000000,"preClose":70.84,"halted":0,"volume":2394963,"hourTrading":{"tag":"盘后","latestPrice":70.8,"preClose":70.8,"latestTime":"19:48 EST","volume":24490,"amount":1733892.7962,"timestamp":1763167724370},"delay":0,"floatShares":112999999,"shares":150675742,"eps":-4.185146,"marketStatus":"已收盘","change":-0.04,"latestTime":"11-14 16:00:00 EST","open":70.8,"high":71.09,"low":70.59,"amount":169695271.01240999,"amplitude":0.007058,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.185146,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1763370000000},"marketStatusCode":5,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":70.84,"preHourTrading":{"tag":"盘前","latestPrice":70.71,"preClose":70.84,"latestTime":"09:02 EST","volume":6,"amount":424.76000999999997,"timestamp":1763128938909},"postHourTrading":{"tag":"盘后","latestPrice":70.8,"preClose":70.8,"latestTime":"19:48 EST","volume":24490,"amount":1733892.7962,"timestamp":1763167724370},"volumeRatio":0.565015,"impliedVol":0.1625,"impliedVolPercentile":0.044},"requestUrl":"/m/hq/s/RNA","defaultTab":"news","newsList":[{"id":"2583742005","title":"Korro Bio的RNA编辑药物例临床结果不佳，引发裁员，诺和诺德暂停合作 | 2025Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2583742005","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583742005?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:13","pubTimestamp":1763115231,"startTime":"0","endTime":"0","summary":"诺和诺德与Korro的合作协议暂停一年，用于重新评估伙伴关系。公告后，Korro Bio股价暴跌近80%，市值大幅缩水；多家投行下调评级。11月13日，Korro Bio公布了其最新财务业绩，同时披露了重大临床挫折。报道指出，作为应对措施，Korro Bio宣布进行公司重组，包括裁减约34%的员工。此次事件导致Korro Bio股价在11月13日开盘后暴跌近80%，从前一交易日收盘价大幅下滑。当天，Korro宣布第三季度末现金流为1.025亿美元，并计划通过裁员约34%来延长现金储备至2027年下半年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114181901a6f94906&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114181901a6f94906&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4505","IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4599","IE00BZ1G4Q59.USD","KRRO","BK4532","NVO","RNA","LU1093756168.USD","BK4139","IE0009354923.USD","BK4588","LU1093756325.SGD"],"gpt_icon":1},{"id":"1189450042","title":"周二关注股票：亚马逊、新纪元、联合健康、英伟达","url":"https://stock-news.laohu8.com/highlight/detail?id=1189450042","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189450042?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:02","pubTimestamp":1761642138,"startTime":"0","endTime":"0","summary":"亚马逊：这家科技公司计划自周二开始裁员多达3万名员工。亚马逊将在周四公布季度财报。然而，股价在盘后交易中下跌。新纪元能源将在今天上午公布财报，而谷歌母公司Alphabet则定于周三公布财报。联合健康、PayPal、皇家加勒比邮轮和联合包裹的财报也将于今天上午发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0823421416.USD","LU1992135399.USD","SG9999014898.SGD","LU2125909916.SGD","BK4561","LU0648000940.SGD","LU1868837300.USD","LU1983260115.SGD","LU0889566641.SGD","LU2360032135.SGD","LU0472753341.HKD","LU1868836914.USD","LU0786609619.USD","LU2462611646.USD","LU2505996681.GBP","LU1244550494.USD","LU0345769631.USD","LU0882574139.USD","LU1951200564.SGD","BK4529","LU0795875169.SGD","LU1861558580.USD","LU1064131342.USD","LU0081259029.USD","BK4585","LU2360106780.USD","LU1674673691.USD","LU2552382132.HKD","LU1989764664.SGD","LU1242518931.SGD","LU0742534661.SGD","LU2125909593.SGD","LU2272731865.HKD","LU2237443622.USD","LU2764262908.HKD","IE00BFXG0V08.USD","LU0820561818.USD","BK4131","LU1629891620.HKD","BK4534","SG9999017495.SGD","LU2236285917.USD","BBBY","BK4567","IE0034235188.USD","SG9999015986.USD","LU0784385840.USD","BK4007","LU2275660780.HKD","LU0289941410.SGD","LU2931357623.SGD","LU2272731600.USD","LU1267930490.SGD","LU2552382215.SGD","LU0976567544.SGD","LU1267930730.SGD","BK4533","LU0719512351.SGD","LU2077746001.SGD","LU2097829019.USD","NVD2.UK","SGXZ81514606.USD","IE00B4JS1V06.HKD","BK4602","LU2023250504.SGD","SG9999018857.SGD","IE00B7SZLL34.SGD","LU1894683264.USD","LU0965509010.AUD","LU1668664300.SGD","LU0823434583.USD","IE00B4R5TH58.HKD","LU0006306889.USD","GB00BDT5M118.USD","LU1551013425.SGD","LU2065171311.SGD","SG9999014575.USD","LU0788109477.HKD","LU1861220207.SGD","LU2430703095.HKD","BK4606","BK4538","LU1496350171.SGD","BK4517","LU0097036916.USD","LU0238689110.USD","LU0823411888.USD","LU1989772840.SGD","LU0912757837.SGD","IE00BMPRXN33.USD","IE00BMG7P926.USD","LU1366192091.USD","HK0000320223.HKD","LU1989771016.USD","NVDL","HK0000306685.HKD","LU1316542783.SGD","LU1585245621.USD","LU0323591593.USD","LU0345770308.USD","LU0316494557.USD","SG9999015952.SGD","UNH","LU0979878070.USD","IE00BK4W5L77.USD","LU1803068623.USD","LU0642271901.SGD","LU1548497426.USD","LU1935043536.SGD","LU2242649171.HKD","LU2433249047.HKD","LU2023250843.SGD","LU2430703178.SGD","LU2750360641.GBP","LU1721428933.USD","LU1861217088.USD","LU0302445910.USD","LU0069063385.USD","LU1914381329.SGD","LU0957791311.USD","LU2294711713.HKD","IE00B775H168.HKD","IE00BD4GTT62.SGD","BK4554","LU1621767810.EUR","IE00BZ9MQY76.HKD","BK4551","LU0980610538.SGD","IE00BD4GTW91.USD","AMZN","LU1116320901.HKD","USJW.SI","LU2491050154.USD","IE00B775SV38.USD","LU0130102774.USD","LU0426412945.USD","LU1489326972.SGD","LU0784384876.USD","LU1043141396.HKD","LU1861215975.USD","LU2247934214.USD","LU0124384867.USD","LU1059921491.USD","LU2473716301.USD","BK4566","BK4587","LU2756315664.SGD","LU2491049909.HKD","LU1718418525.SGD","IE00B29SXL02.USD","LU2111349929.HKD","BK4077","LU0957808578.USD","LU1037948897.HKD","RNA","LU1861220033.SGD","LU0157215616.USD","LU0417517546.SGD","LU1244550221.USD","NVDA","LU0683600562.USD","SG9999014914.USD","LU1066053197.SGD","LU1366333091.USD","BK4579","LU0289961442.SGD","LU1989764748.USD","LU0310800379.SGD","LU2720916845.USD","BK4573","LU1670627923.USD","LU0314104364.USD","LU0198837287.USD","IE00B894F039.SGD","LU0823414551.USD","LU2413666699.HKD","BK4142","BK4503","BK4614","IE00B19Z9505.USD","IE00BKVL7J92.USD","GOOGL","NVIW.SI","LU2360107168.USD","LU0310799852.SGD","LU0029864427.USD","GOOG","LU1235294995.USD","LU2746668461.USD","LU0965509101.SGD","LU0985320562.USD","LU2237957902.USD","SG9999004303.SGD","LU2500361329.USD","LU0107464264.USD","LU0106261372.USD","LU2403377893.USD","LU2322448957.HKD","LU0348723411.USD","LU2191332357.HKD","LU2491050071.SGD","LU0312595415.SGD","IE00B19Z3581.USD","LU2089984988.USD","SG9999001176.SGD","LU0096362180.USD","LU1674673428.USD","IE0004445015.USD","LU0225283273.USD","SG9999015945.SGD","LU0210528500.USD","LU0965509283.SGD","IE000YTNTUN2.SGD","IE00B4YYXB79.USD","LU2083900584.USD","LU0690374961.EUR","LU0964807845.USD","BK4596","IE00BMPRXR70.SGD","LU1791710582.SGD","LU0109392836.USD","BK4576","LU0211331839.USD","LU1267930227.SGD","IE00BFSS8Q28.SGD","IE00BMG7P587.USD","LU1196500208.SGD","IE0004445239.USD","LU2756315318.SGD","LU1815336760.USD","IE0005OL40V9.USD","LU1935042488.USD","LU2452424414.USD","LU2487616109.SGD","LU0256863902.USD","LU1791710400.SGD","LU0208291251.USD","LU0345768740.USD","GB00B4QBRK32.GBP","LU0354030438.USD","LU2750360997.AUD","BK4598","IE00BHPRN162.USD","IE00BKPKM429.USD","LU0234572021.USD","LU0689472784.USD","LU2417539215.USD","IE00BD6J9T35.USD","LU0122379950.USD","LU0528227936.USD","LU2896262040.SGD","LU0868494617.USD","BK4559","LU1280957306.USD","LU2168564222.USD","LU2272731782.SGD","LU2463028550.USD","LU2381873111.SGD","LU0823414478.USD","LU0795875086.SGD","BK4553","IE0034235295.USD","LU1242518857.USD","BK4139","LU2168564495.EUR","IE00BMPRXQ63.HKD","LU1035775433.USD","LU0256863811.USD","LU1046421795.USD","LU1642822529.SGD","LU1621768206.USD","LU2065170008.USD","LU2112291526.USD","LU0251132253.USD","LU0444973449.USD","IE00BN29S564.USD","LU2471134952.CNY","LU0203345920.USD","BK4532","LU2237957811.SGD","LU0466842654.USD","LU0124676726.USD","LU1732800096.USD","LU0354030511.USD","IE00B2B36J28.USD","LU2097344431.USD","LU0080751232.USD","IE00B3SWFQ91.USD","LU0477156797.USD","LU2322448791.USD","LU1043141123.HKD","BK4547","LU0061475181.USD","LU0211326839.USD","LU0553294199.USD","LU0128525689.USD","LU0158827948.USD","LU0289960550.SGD","LU1929549753.HKD","LU1880398554.USD","IE00BQXX3D17.EUR","HK0000320264.USD","LU1732799900.SGD","LU2125154935.USD","BK4597","LU2298064838.USD","LU2764263203.CNY","LU2543165471.USD","LU2023251221.USD","LU1861127337.USD","LU2211814178.USD","LU2420271590.USD","LU2250418816.HKD","LU0072461881.USD","LU1923622291.USD","RCL","LU1116320737.USD","LU1974910355.USD","SG9999013999.USD","LU0114720955.EUR","IE00B19Z9Z06.USD","IE00BDCRKT87.USD","IE000M9KFDE8.USD","LU2384288077.EUR","LU0545039389.USD","IE000ITXATA3.USD","IE00B19Z3B42.SGD","NVS","LU1880398471.USD","LU2237443978.SGD","LU0310800965.SGD","LU2237443549.SGD","LU1074936037.SGD","LU0648001328.SGD","IE00BJTD4V19.USD","LU2360107671.USD","LU0345768153.USD","LU1496350502.SGD","IE00BFXG1179.USD","LU1854104046.USD","LU2048586759.USD","IE00BJJMRX11.SGD","LU0106831901.USD","BK4548","LU0347712357.USD","IE00BGHQF417.EUR","LU0820562030.AUD","LU1571399168.USD","LU0266013472.USD","LU2361044949.HKD","SG9999014559.SGD","LU1821325948.USD","SG9999000418.SGD","LU2362540622.SGD","LU0878866978.SGD","LU0690374615.EUR","LU0994945656.USD","SG9999014906.USD","LU0079474960.USD","IE00BZ1G4Q59.USD","LU0949170772.SGD","IE000W1ABFV2.USD","LU1201861249.SGD","LU0289739343.SGD","IE00BJTD4N35.SGD","LU2362541513.USD","LU2462157665.USD","LU1037948541.HKD","LU1201861165.SGD","LU2249611893.SGD","HK0000306701.USD","LU0162691827.USD","LU0127658192.USD","SNVD.UK","LU1232071149.USD","LU2746668974.SGD","IE00B19Z8X17.USD","IE00B5TLWC47.USD","LU1023059063.AUD","NVDX","LU0210533765.USD","LU1917777945.USD","LU2237443382.USD","LU2242650005.HKD","GB00B4LPDJ14.GBP","IE00BKDWB100.SGD","LU0882574055.USD","LU1691799644.USD","LU1720051108.HKD","IE00BQXX3C00.GBP","IE0003U64NQ7.SGD","SG9999014542.SGD","LU0072462426.USD","IE00B3M56506.USD","LU1066051498.USD","LU1551013342.USD","LU2471134796.USD","LU0170899867.USD","LU0345774391.USD","LU2168564065.EUR","IE00BK4W5M84.HKD","LU2089283258.USD","BK4178","LU2298322129.HKD","LU2125909759.SGD","LU0724618433.USD","LU1093756168.USD","LU2430703251.USD","SG9999014567.USD","LU0130517989.USD","LU1221951046.USD","LU1935043023.USD","BK4605","LU1989772923.USD","LU0345774631.USD","LU1506573853.SGD","LU2023250330.USD","IE00BLSP4452.SGD","LU0289739699.SGD","LU1069344957.HKD","LU0094547139.USD","LU2347655156.SGD","SG9999002224.SGD","LU0724617625.USD","LU0211326755.USD","LU0942090050.USD","LU1066051225.USD","LU2458330169.SGD","LU2592432038.USD","LU1934455863.HKD","IE00B5949003.HKD","BK4608","LU1923622614.USD","SG9999001077.SGD","LU2764263039.SGD","LU0689626769.HKD","LU1323610961.USD","LU0390134368.USD","BK4505","LU2552382058.USD","LU0265550946.USD","LU1119994496.HKD","BK4578","LU0109391861.USD","LU2168564149.EUR","IE0009355771.USD","LU2637428348.USD","LU2065171402.SGD","LU0345769128.USD","IE00BYQQ9H92.USD","LU0274383776.USD","LU0149725797.USD","LU1162221912.USD","LU1712237335.SGD","LU2404859667.USD","SG9999002232.USD","BK4574","LU0868494708.USD","LU2089985449.USD","LU2213496289.HKD","LU2471134879.HKD","WHR","LU2237443465.HKD","LU1303367103.USD","LU1951198990.SGD","LU1221951129.SGD","LU1670628061.USD","LU1868837136.USD","LU2362541273.HKD","LU1815333072.USD","LU2456880835.USD","IE00BMG7P694.USD","NVDS.UK","LU0251142724.SGD","LU1983299246.USD","SGXZ23171101.USD","LU1621768115.EUR","LU2237443895.HKD","LU1854103824.USD","LU1301847155.USD","LU2106854487.HKD","BK4081","IE0009G5SDU7.USD","LU2286300806.USD","LU0792757196.USD","SG9999018865.SGD","LU0787776722.HKD","LU2404859741.USD","LU1883866441.USD","NVDD","BK4122","IE00BLSP4239.USD","IE00BFTCPJ56.SGD","NVDU","BK4535","USAW.SI","IE0002141913.USD","LU0077335932.USD","LU1894683348.USD","LU1066051811.HKD","LU1934455194.USD","LU2092937148.SGD","IE00BZ199S13.USD","LU0511384066.AUD","LU1267930573.SGD","LU2458330243.SGD","NVDS","BK4154","BK4581","LU2602419157.SGD","LU0130518102.USD","IE00B1XK9C88.USD","LU1623119135.USD","LU0823434740.USD","LU1778281490.HKD","LU2326559502.SGD","LU1934455277.USD","IE00BMG7P819.SGD","LU2860962120.EUR","IE00B2PGVK34.USD","LU0433182093.SGD","LU1804176565.USD","LU0211327993.USD","IE00BN8TJ469.HKD","IE0034235303.USD","IE00B7KXQ091.USD","LU0267386448.USD","LU0175139822.USD","LU0640476718.USD","SG9999001176.USD","IE0009356076.USD","LU1699723380.USD","LU0130103400.USD","LU0061474960.USD","3NVD.UK","LU2237438978.USD","LU1992135472.HKD","LU1939255532.USD","IE00BJJMRY28.SGD","LU0203202063.USD","LU1435385759.SGD","LU1823568750.SGD","SG9999015341.SGD","BK4549","BK4588","2NVD.UK","LU0154236417.USD","LU1861559042.SGD","LU0210536198.USD","LU1093756325.SGD","LU0661504455.SGD","LU0048584097.USD","LU0476273544.USD","SGXZ57979304.SGD","SG9999001424.SGD","LU1127390331.HKD","BK4550","LU0353189763.USD","LU0011850046.USD","LU0057025933.USD","LU2168563687.JPY","LU2361044865.SGD","LU0048573561.USD","BK4525","LU0070217475.USD","LU1720051017.SGD","LU1852331112.SGD","LU0889565833.HKD","BK4106","LU2211815571.USD","SGXZ51526630.SGD","LU2063271972.USD","NVD3.UK","IE00B19Z9P08.USD","LU2092627202.USD","LU1868836591.USD","LU2361045086.USD","IE00BJLML261.HKD","LU2089284900.SGD","BK4612","LU2357125470.USD","LU1923623000.USD","LU0203347892.USD","LU0211328371.USD","LU0738911758.USD","LU0985489474.SGD","LU1430594728.SGD","LU0444971666.USD","LU0320765489.SGD","IE00BFSS7M15.SGD","LU0128525929.USD","BK4507","LU1868836757.USD","LU0082616367.USD","UPS","LU0949170426.SGD","SG9999015978.USD","LU0456855351.SGD","LU0494093205.USD","LU2028103732.USD","LU1291159041.SGD","LU0823416689.USD","LU1814569148.SGD","LU0557290698.USD","LU2290526834.HKD","LU2506951792.HKD","LU2271345857.HKD","LU0096364046.USD","LU0820561909.HKD","LU2125909247.SGD","LU0342679015.USD","LU0320765059.SGD","PYPL","LU2468319806.SGD","LU0943347566.SGD","LU0784383803.USD","LU1057294990.SGD","IE00B3CCJ633.GBP","SG9999015358.SGD","LU0314106906.USD","LU1935042215.USD","LU2264538146.SGD","SGXZ99366536.SGD","LU1429558221.USD","LU1261432733.SGD","IE000KEQY171.SGD","IE00BJJMRZ35.SGD","LU0052756011.USD","LU2087621335.USD","IE00B1BXHZ80.USD","LU2097344357.USD","SGXZ31699556.SGD","LU0965508806.USD","LU0477156953.USD","LU2505996509.AUD","LU1633808545.USD","BK4220","LU2265009873.SGD","LU1032955483.USD","IE00B3S45H60.SGD","IE00BMG7P702.HKD","LU0308772762.SGD","IE00BSNM7G36.USD","LU1803068979.SGD","LU2394011477.USD","LU1988902786.USD","LU1084165304.USD","BK4227","LU0068578508.USD","LU1791807156.HKD","LU2065169927.USD","BK4514","LU0061474705.USD","LU1061106388.HKD","LU0861579265.USD","LU0345770993.USD","LU0708995401.HKD","LU1244550577.SGD","BK4604","IE00BBT3K403.USD","LU0215105999.USD","LU0672654240.SGD","LU1121112475.USD","LU1003077747.HKD","LU2317271919.USD","SG9999014880.SGD","LU0070302665.USD","IE00BWXC8680.SGD","IE0002270589.USD","LU2279689827.SGD","LU1069347547.HKD","IE00B29SXK94.USD","LU0056508442.USD","LU0426417589.USD","LU2471134523.USD","IE00BD4GTV84.USD","LU0053666078.USD","LU0251131958.USD","LU1035773651.USD","LU2244417387.USD","LU0265550359.USD","LU2133065610.SGD","BK4592","BK4191","LU2054465674.USD","IE0004086264.USD","IE0004091025.USD","LU2108987350.USD","BK4527","LU0203201768.USD","LU2413666426.HKD","LU2357305700.SGD","LU0320765646.SGD","BK4141","IE00BJT1NW94.SGD","LU0234570918.USD","LU2098885051.SGD","NVD","LU0784385170.HKD","LU0276348264.USD","LU1978683503.SGD","LU1839511570.USD","LU0158827781.USD","LU0187121727.USD","LU1621767737.EUR","LU1267930813.SGD","NEE","LU0432979614.USD","LU1935042991.SGD","LU2498475776.HKD","LU0353189680.USD","LU2125154778.USD","BK4543","LU0496365809.HKD","LU1145028129.USD","IE00B19Z8W00.USD","IE00BDRTCR15.USD","LU0708994859.HKD","LU2238339852.HKD","LU2324357040.USD","BK4524","LU2087625088.SGD","NVDY","LU0823421333.USD","IE00BYXW3230.USD","IE00BQXX3F31.USD","LU2461242641.AUD","LU1153585028.USD"],"gpt_icon":1},{"id":"1113634984","title":"Avidity Biosciences, Inc.：RBC将其目标评级从“跑赢大盘”下调至“行业表现”，并将目标价从61美元上调至72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113634984","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113634984?lang=zh_cn&edition=full","pubTime":"2025-10-28 13:11","pubTimestamp":1761628270,"startTime":"0","endTime":"0","summary":"Avidity Biosciences, Inc.：RBC将其目标评级从“跑赢大盘”下调至“行业表现”，并将目标价从61美元上调至72美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4588","BK4585","BK4505","BK4139"],"gpt_icon":0},{"id":"1187667451","title":"Avidity Biosciences Inc ：Leerink Partners 将评级从“跑赢大盘”下调至“市场表现”；目标价格上调至72美元，从65美元提高","url":"https://stock-news.laohu8.com/highlight/detail?id=1187667451","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187667451?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:44","pubTimestamp":1761576252,"startTime":"0","endTime":"0","summary":"Avidity Biosciences Inc ：Leerink Partners 将评级从“跑赢大盘”下调至“市场表现”；目标价格上调至72美元，从65美元提高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","BK4588","RNA","BK4139"],"gpt_icon":0},{"id":"1181059515","title":"诺华首席执行官表示公司计划与美国FDA讨论对Avidity纤维肌痛症治疗的加速审批潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1181059515","media":"美股速递","labels":["executive","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181059515?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:49","pubTimestamp":1761569351,"startTime":"0","endTime":"0","summary":"诺华首席执行官表示公司计划与美国FDA讨论对Avidity纤维肌痛症治疗的加速审批潜力","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","RNA","BK4585","BK4505","BK4139"],"gpt_icon":0},{"id":"1175719093","title":"Avidity Biosciences- 在特定情况下合并与诺华终止时，公司需向诺华支付4.5亿美元的终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1175719093","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175719093?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:32","pubTimestamp":1761564729,"startTime":"0","endTime":"0","summary":"Avidity Biosciences- 在特定情况下合并与诺华终止时，公司需向诺华支付4.5亿美元的终止费","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"03493874a4eadea936a603e5a022bfa9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4139","BK4505","BK4585","BK4588"],"gpt_icon":0},{"id":"1143719887","title":"Avidity Biosciences Inc：Bernstein下调评级至市场表现，从跑赢大盘调整至$72目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1143719887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143719887?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:08","pubTimestamp":1761556091,"startTime":"0","endTime":"0","summary":"Avidity Biosciences Inc：Bernstein下调评级至市场表现，从跑赢大盘调整至$72目标价，上调目标价格至$72，从$52上调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","RNA","BK4139","BK4505"],"gpt_icon":0},{"id":"2578374669","title":"120亿美元拿下“罕见病专家”Avidity，医药巨头诺华同意历史上最大笔收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2578374669","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578374669?lang=zh_cn&edition=full","pubTime":"2025-10-27 08:31","pubTimestamp":1761525108,"startTime":"0","endTime":"0","summary":"诺华以120亿美元收购罕见病生物技术公司Avidity，创公司十多年最大收购案，溢价46%。Avidity三种在研药物预计2030年前上市，峰值年销售额可达数十亿美元，将助力诺华应对专利悬崖。此次交易将诺华2024-2029年复合年增长率从5%提升至6%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3757939","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d983b7f77c56e019b628a01bf1a49d41","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3757939","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"120亿美元拿下“罕见病专家”Avidity，医药巨头诺华同意历史上最大笔收购","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","NVS"],"gpt_icon":1},{"id":"2577591811","title":"石药集团(01093)：SYH2061注射液(双链小干扰RNA药物)在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2577591811","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577591811?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:33","pubTimestamp":1761298432,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主研发的化学1类新药SYH2061注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4505","LU1008478684.HKD","BK1521","LU1226288253.USD","IE00B5MMRT66.SGD","LU1328277881.USD","LU0314109678.HKD","LU0072913022.USD","IE0008369823.USD","LU0140636845.USD","LU0326950275.SGD","LU0067412154.USD","LU1152091754.HKD","LU1226287875.USD","LU0315179316.USD","IE00B543WZ88.USD","LU1813983027.USD","LU1951186391.HKD","LU1807302812.USD","LU1226287792.SGD","IE0008368742.USD","LU2039709279.SGD","BK1191","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00BZ08YS42.EUR","BK4139","LU1960683339.HKD","SG9999004220.SGD","LU1152091168.USD","BK1515","LU1226287529.USD","BK4585","BK4588","IE00BZ08YT58.USD","IE00B031HY20.USD","RNA","LU0880133367.SGD","01093","LU1993786604.SGD","LU0501845795.SGD"],"gpt_icon":0},{"id":"1165649055","title":"Avidity Biosciences宣布Del-Zota治疗DMD44获得美国FDA积极的生物制品许可申请预备会议反馈，计划于2026年第一季度提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1165649055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165649055?lang=zh_cn&edition=full","pubTime":"2025-10-13 21:01","pubTimestamp":1760360483,"startTime":"0","endTime":"0","summary":"Avidity Biosciences宣布，该公司针对Del-Zota治疗DMD44适应症与美国食品药品监督管理局(FDA)举行的生物制品许可申请预备会议取得积极进展。公司计划于2026年第一季度正式提交相关申请。\n这一积极的监管里程碑为Del-Zota在DMD44治疗领域的后续开发奠定了重要基础，标志着该疗法向商业化迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","RNA","BK4585","BK4139"],"gpt_icon":0},{"id":"2574153882","title":"石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2574153882","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574153882?lang=zh_cn&edition=full","pubTime":"2025-10-09 18:09","pubTimestamp":1760004572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的化学1类新药SYH2070注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。该产品亦于2025年9月获得中华人民共和国国家药品监督管理局批准在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0315179316.USD","BK4588","LU0326950275.SGD","RNA","LU1152091754.HKD","LU1328277881.USD","BK4139","LU1226287529.USD","LU1807302812.USD","LU0072913022.USD","IE0008369823.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU1152091168.USD","LU1226288253.USD","LU1960683339.HKD","LU1951186391.HKD","BK1515","SG9999004220.SGD","LU0067412154.USD","BK4505","IE00BZ08YR35.GBP","LU1813983027.USD","LU0140636845.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","IE0008368742.USD","01093","IE00B031HY20.USD","LU1993786604.SGD","LU1226287792.SGD","BK1521","LU1226287875.USD","BK4585","LU1008478684.HKD","LU1226288170.HKD","LU2039709279.SGD","LU0314109678.HKD","IE00B543WZ88.USD","LU0501845795.SGD","BK1191"],"gpt_icon":0},{"id":"2571348951","title":"石药集团(01093)：SYH2070注射液(双链小干扰RNA药物)在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2571348951","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571348951?lang=zh_cn&edition=full","pubTime":"2025-09-30 17:30","pubTimestamp":1759224612,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的化学1类新药SYH2070注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","BK1521","LU1226288253.USD","LU1008478684.HKD","LU0326950275.SGD","LU0880133367.SGD","01093","LU0067412154.USD","LU1951186391.HKD","LU2039709279.SGD","LU1960683339.HKD","LU1993786604.SGD","IE00B031HY20.USD","IE0008368742.USD","LU1226288170.HKD","LU1226287792.SGD","IE00BZ08YS42.EUR","SG9999004220.SGD","BK4139","BK4505","LU0072913022.USD","LU0314109678.HKD","LU1226287875.USD","RNA","IE0008369823.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","LU1328277881.USD","BK4588","LU1807302812.USD","LU0315179316.USD","LU0501845795.SGD","BK4585","IE00BZ08YT58.USD","LU1226287529.USD","BK1515","IE00B543WZ88.USD","LU0140636845.USD","BK1191","LU1152091168.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2570159885","title":"Avidity Biosciences, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570159885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570159885?lang=zh_cn&edition=full","pubTime":"2025-09-26 00:50","pubTimestamp":1758819015,"startTime":"0","endTime":"0","summary":"北京时间2025年09月26日00时50分，Avidity Biosciences, Inc.股票出现波动，股价急速下跌5.02%。Avidity Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.28%。其相关个股中，Pepgen Inc.、Scisparc Ltd.、Plus Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Evaxion A/S、Qualigen Therapeutics, Inc.较为活跃，换手率分别为5085.71%、1154.52%、676.93%，振幅较大的相关个股有Scisparc Ltd.、Geovax Labs Inc C/Wts 29/09/2025、Pepgen Inc.，振幅分别为91.12%、70.59%、54.14%。Avidity Biosciences, Inc.公司简介：Avidity Biosciences Inc 是一家生物制药公司，致力于提供一类称为抗体寡核苷酸偶联物 的新型 RNA 疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509260050159545180d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509260050159545180d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4505","BK4139","RNA","BK4588"],"gpt_icon":0},{"id":"2567116705","title":"募资5亿美元加码核心管线！Avidity(RNA.US)获美银唱好 目标价看高至65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2567116705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567116705?lang=zh_cn&edition=full","pubTime":"2025-09-15 11:59","pubTimestamp":1757908750,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国银行发表研报，予以Avidity Biosciences Inc. “买入”评级，并将目标价从56美元上调至65美元。该行表示，Avidity Biosciences当前股价的回调，为投资者提供了大举增持该股的重要机遇。此次评级与目标价调整，源于Avidity Biosciences此前宣布拟发行价值5亿美元的股票。据了解，Avidity Biosciences是一家专注于AOC研发的生物制药公司，其核心业务是通过RNA疗法治疗罕见病和肌肉疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"募资5亿美元加码核心管线！Avidity(RNA.US)获美银唱好 目标价看高至65美元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RNA"],"gpt_icon":0},{"id":"2566085789","title":"Avidity宣布已完成6亿美元股票发行的定价","url":"https://stock-news.laohu8.com/highlight/detail?id=2566085789","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566085789?lang=zh_cn&edition=full","pubTime":"2025-09-12 23:20","pubTimestamp":1757690400,"startTime":"0","endTime":"0","summary":"生物技术企业Avidity生物科学公司（RNA）早盘上涨6.7%，此前该公司宣布已完成6亿美元股票发行的定价，以推进其临床项目并扩大商业基础设施。所筹资金将用于支持其AOC平台的开发及潜在产品上市，为公司的未来增长奠定基础。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-12/doc-infqhchz7363567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RNA","BK4585","BK4139","BK4588","BK4505"],"gpt_icon":0},{"id":"2566704229","title":"生物技术企业Avidity生物科学公司（RNA）宣布已完成6亿美元股票发行的定价以推进其临床项目并扩大商业基础设施。所筹","url":"https://stock-news.laohu8.com/highlight/detail?id=2566704229","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566704229?lang=zh_cn&edition=full","pubTime":"2025-09-12 22:59","pubTimestamp":1757689140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BK4505","RNA","BK4139","BK4585"],"gpt_icon":0},{"id":"1151630332","title":"Avidity Biosciences的Del-Zota在Explore44®和Explore44-Ole™ 1/2期试验中证实在关键功能终点实现了Dmd44患者疾病进展的逆转","url":"https://stock-news.laohu8.com/highlight/detail?id=1151630332","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151630332?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:02","pubTimestamp":1757502128,"startTime":"0","endTime":"0","summary":"Avidity Biosciences的Del-Zota在Explore44®和Explore44-Ole™ 1/2期试验中证实在关键功能终点实现了Dmd44患者疾病进展的逆转","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","BK4505","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2565516548","title":"10x基因组学取得使用RNA模板化连接进行空间分析的方法专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2565516548","media":"市场资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565516548?lang=zh_cn&edition=full","pubTime":"2025-09-06 16:32","pubTimestamp":1757147576,"startTime":"0","endTime":"0","summary":"国家知识产权局信息显示，10x基因组学有限公司取得一项名为“使用RNA模板化连接进行空间分析的方法”的专利，授权公告号CN 114885610 B，申请日期为2020年12月。声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/06163252973197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4585","BK4139","BK4505","RNA","BK4588"],"gpt_icon":0},{"id":"2563408028","title":"诺和诺德新CEO上任三把火，5.5亿美元押注RNA技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2563408028","media":"MedTrend医趋势","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563408028?lang=zh_cn&edition=full","pubTime":"2025-08-29 18:25","pubTimestamp":1756463138,"startTime":"0","endTime":"0","summary":"8月28日，其上任后的首次并购交易成功落地，聚焦于新型RNA技术领域。作为肥胖症治疗领域的先行者，诺和诺德在下一代药物的研发竞赛中逐渐面临挑战，如今该公司正寄望于新型RNA技术，以强化其早期研发管线。诺和诺德已与Replicate生物科学公司签署了一项为期多年的研究合作协议，协议潜在总价值高达5.5亿美元。根据该声明，Replicate将获得一笔预付款，若后续达到相关里程碑节点，还可获得额外款项，协议总价值最高可达5.5亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829194940a4a7b5c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250829194940a4a7b5c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4588","LU1093756325.SGD","BK4505","LU0154236417.USD","NVO","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","BK4007","RNA","IE00BZ1G4Q59.USD","BK4139","O","BK4585"],"gpt_icon":1},{"id":"2560273279","title":"中慧生物CHO细胞新药临床试验获中美当局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2560273279","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560273279?lang=zh_cn&edition=full","pubTime":"2025-08-17 22:20","pubTimestamp":1755440409,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","LU1223083913.SGD","IND.AU","LU1223082519.USD","BK7095","LU1223082196.USD","RNA","CDE","BK4505","159646","BK4139","BK7050","CDE.AU","BK4588","BK4017"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aviditybiosciences.com","stockEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":0.4718},{"period":"3month","weight":0.5244},{"period":"6month","weight":1.3341},{"period":"1year","weight":0.3493},{"period":"ytd","weight":1.436}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.0148},{"period":"3month","weight":0.0444},{"period":"6month","weight":0.131},{"period":"1year","weight":0.1253},{"period":"ytd","weight":0.1467}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avidity Biosciences, Inc.是根据特拉华州法律于2012年11月13日成立的。该公司是一家生物制药公司。公司开创了一种新型的基于寡核苷酸的疗法，称为抗体寡核苷酸缀合物（AOC），旨在克服寡核苷酸疗法的当前局限性，以治疗多种严重的疾病。该公司利用其专有的AOC平台来设计，策划和开发结合单克隆抗体（mAbs）的组织选择性和寡核苷酸疗法的精确性的疗法，以访问以前无法吸收的组织和细胞类型，并更有效地针对疾病的潜在遗传驱动因素。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.029515},{"month":2,"riseRate":0.6,"avgChangeRate":0.100374},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.094524},{"month":12,"riseRate":0.6,"avgChangeRate":0.131559}],"exchange":"NASDAQ","name":"Avidity Biosciences, Inc.","nameEN":"Avidity Biosciences, Inc."},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avidity Biosciences, Inc.(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avidity Biosciences, Inc.(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avidity Biosciences, Inc.,RNA,Avidity Biosciences, Inc.股票,Avidity Biosciences, Inc.股票老虎,Avidity Biosciences, Inc.股票老虎国际,Avidity Biosciences, Inc.行情,Avidity Biosciences, Inc.股票行情,Avidity Biosciences, Inc.股价,Avidity Biosciences, Inc.股市,Avidity Biosciences, Inc.股票价格,Avidity Biosciences, Inc.股票交易,Avidity Biosciences, Inc.股票购买,Avidity Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avidity Biosciences, Inc.(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avidity Biosciences, Inc.(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}